NASDAQ:SANA Sana Biotechnology Q3 2025 Earnings Report $2.83 -0.02 (-0.70%) Closing price 04:00 PM EasternExtended Trading$2.84 +0.01 (+0.49%) As of 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Sana Biotechnology EPS ResultsActual EPS-$0.15Consensus EPS -$0.18Beat/MissBeat by +$0.03One Year Ago EPSN/ASana Biotechnology Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASana Biotechnology Announcement DetailsQuarterQ3 2025Date11/6/2025TimeBefore Market OpensConference Call DateThursday, November 6, 2025Conference Call Time7:00AM ETUpcoming EarningsSana Biotechnology's Q2 2026 earnings is estimated for Monday, August 10, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Sana Biotechnology Earnings HeadlinesHarbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific AdvisorJune 12, 2026 | finance.yahoo.comAs the GLP-1 race heats up, how can investors position themselves for the next wave of innovation?June 10, 2026 | msn.comRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the largest mineral reserve in the country - enough gold for a new Fort Knox, enough copper to rebuild the U.S. electric grid 25 times over. The Trump administration has previously staked positions in MP Materials, Lithium America, Trilogy Metals, and USA Rare Earth - each time shares moved higher. A landmark policy decision expected before June 30 could reprice this stock from $2 to $20 or more within a year.June 16 at 1:00 AM | Paradigm Press (Ad)Sana Biotechnology, Inc. (SANA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 10, 2026 | seekingalpha.comSana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Rating of "Moderate Buy" by AnalystsJune 7, 2026 | americanbankingnews.comSana Biotechnology (NASDAQ:SANA) Downgraded by Wall Street Zen to SellJune 7, 2026 | americanbankingnews.comSee More Sana Biotechnology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sana Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sana Biotechnology and other key companies, straight to your email. Email Address About Sana BiotechnologySana Biotechnology (NASDAQ:SANA) is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function. The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9. Sana’s ex vivo pipeline includes allogeneic cell programs designed to target hematologic malignancies and solid tumors, while its in vivo portfolio focuses on directly delivering therapeutic genes to tissues for the treatment of hereditary diseases. Preclinical research efforts span multiple therapeutic areas, with a view to advancing candidates into human trials. Founded in 2018 as an independent enterprise originating from the life-science incubator Flagship Pioneering, Sana Biotechnology is headquartered in Seattle, Washington, with research and development facilities in Cambridge, Massachusetts. Its global operations support collaborative partnerships and research alliances aimed at accelerating the translation of cell therapies from the laboratory to the clinic. Under the leadership of Chief Executive Officer Steve Harr, Sana has assembled a multidisciplinary management team with expertise in biotechnology, immunology and drug development. The company continues to expand its scientific and manufacturing capabilities while advancing a pipeline intended to address unmet medical needs and improve long-term patient outcomes.View Sana Biotechnology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Okta’s AI Moment May Be Bigger Than Investors RealizeStrategy’s Bitcoin Rally Has a Hidden EngineIs Lennar Finally Turning the Corner After Its Housing Slump?Can D-Wave Hold Its Own Against 2 Fast-Growing Rivals?This Golden Cross Could Send Urban Outfitters to New Highs3 Dividend Increases Investors Can Actually TrustRH’s Strong Q1 Still Leaves Investors With One Big Question Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
